

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4765739

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	AAIPHARMA SERVICES CORP.	02/17/2017
RECEIVING PARTY DATA		
Name:	AGENEBIO, INC.	
Street Address:	1101 E. 33RD STREET, SUITE C310	
City:	BALTIMORE	
State/Country:	MARYLAND	
Postal Code:	21218	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	PCT Number:	US2016033567
CORRESPONDENCE DATA		
Fax Number:	(646)219-6229	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(646)973-2500	
Email:	HGPatentDocket@hglaw.com	
Correspondent Name:	HALEY GUILIANO LLP	
Address Line 1:	75 BROAD STREET, SUITE 1000	
Address Line 4:	NEW YORK, NEW YORK 10004	
ATTORNEY DOCKET NUMBER:	107042-0021-WO1	
NAME OF SUBMITTER:	LILY JIANG	
SIGNATURE:	/Lily Jiang/	
DATE SIGNED:	01/08/2018	
Total Attachments: 5		
source=107042-0021-WO1 signed PCT Assignment - AAIPS to AgeneBio#page1.tif		
source=107042-0021-WO1 signed PCT Assignment - AAIPS to AgeneBio#page2.tif		
source=107042-0021-WO1 signed PCT Assignment - AAIPS to AgeneBio#page3.tif		
source=107042-0021-WO1 signed PCT Assignment - AAIPS to AgeneBio#page4.tif		
source=107042-0021-WO1 signed PCT Assignment - AAIPS to AgeneBio#page5.tif		

PCT
ASSIGNMENT

We, AAIPHARMA SERVICES CORP. ("AAIPHARMA"), a corporation organized and existing under the laws of the State of Delaware, and having an office and a place of business at 2320 Scientific Park Drive, Wilmington, North Carolina 28405, USA, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to AGENE BIO, INC., an entity organized and existing under the laws of the State of Delaware and having an office and a place of business at 1103 E. 33rd Street, Suite C310, Baltimore, Maryland 21218, USA, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all our inventions and discoveries disclosed in our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US) on May 20, 2016, assigned application number PCT/US2016/033567, entitled: "EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM", and designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Brunei Darussalam (BN), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Comoros (KM), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Iran (IR), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libyan Arab Jamahiriya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), the Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint Kitts and Nevis (KN), Saint Lucia

(LC), Saint Vincent and the Grenadines (VC), San Marino (SM), Sao Tome and Principe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), Thailand (TH), The former Yugoslav Republic of Macedonia (MK), Togo (TG), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United Republic of Tanzania (TZ), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW), and all other PCT member states, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefore; (2) the full and complete right to file patent applications in the name of AGENE BIO, INC., its designee, or in our names at AGENE BIO, INC., or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application:

<u>Application No.</u>	<u>Country</u>	<u>Filing Date</u>
62/165,812	United States of America	May 22, 2015
15/160,424	United States of America	May 20, 2016

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to AGENE BIO, INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.


We agree, at any time, upon the request of AGENE BIO, INC. to execute and to deliver to AGENE BIO, INC. any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree, at any time, upon request of AGENEBIO, INC. to execute and to deliver to AGENEBIO, INC. such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of AGENEBIO, INC. under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

It is our intention that this Assignment be effective and all rights transferred herein shall be considered to have vested in AGENEBIO, INC. no later than May 22, 2015, the date of the earliest priority chain.

ASSIGNOR:


AAIPHARMA SERVICES CORP.



Name: R. Scott Warner
Title: VP Reg. & Asst. Secretary
Date: 17 February 2017

State of North Carolina
County of New Hanover

On this 17th day of February, 2017, before me, the undersigned
notary public, personally appeared R. Scott Warner, proved to me through
satisfactory evidence of identification, which was known to me, to be the
person whose name is signed on the preceding or attached document in my presence.

(SEAL)




Notary Public

My commission expires June 26, 2019.

ACKNOWLEDGEMENT OF ASSIGNEE:


I hereby acknowledge the foregoing executed Assignment on behalf of AGENE BIO, INC.

By: Gerald W. McLaughlin Jr.
Name: Gerald W. McLaughlin Jr.
Title: President & CEO

Date: 05 JAN 2018

State of PA)
County of Bucks)

On this 5 day of January, 2018, before me, the undersigned notary public, personally appeared Gerald McLaughlin Jr., proved to me through satisfactory evidence of identification, which was driver's license, to be the person whose name is signed on the preceding or attached document in my presence.



[Signature]
Notary Public

My commission expires 10/13/18